Published 08/07/2024 6:26:11 a.m.

Wegovy maker Novo Nordisk posts earnings miss, cuts operating profit outlook

Summary

Novo Nordisk on Wednesday posted weaker-than-expected net profit in the second quarter and trimmed its operating profit outlook.The pharmaceutical giant said its net profit came in at 20.05 billion Danish kroner ($2.93 billion) in the three months to the end of June. A LSEG aggregate forecast had projected the figure would come in at 20.9 billion Danish kroner.

0 Articles

All

Left

Center

Right

Reuters

Obesity drugmaker Novo Nordisk misses Q2 profit forecast

Novo Nordisk on Wednesday posted second-quarter operating profit below expectations, raised its 2024 sales forecast but trimmed profit outlook, as competition from Eli Lilly in the booming weight-loss drug market intensifies.

08/07/2024 6:26:11 a.m.·United Kingdom

Read Full Article

CNBC

Wegovy maker Novo Nordisk posts earnings miss, cuts operating profit outlook

Novo Nordisk on Wednesday announced its second quarter earnings for 2024.

08/07/2024 5:48:07 a.m.·United States

Read Full Article

RTÉ

Obesity drugmaker Novo Nordisk misses Q2 profit forecast

Novo Nordisk has today posted second-quarter operating profit below expectations, raised its 2024 sales forecast but cut profit outlook, as competition from Eli Lilly in the booming weight-loss drug market intensifies.

08/07/2024 6:10:10 a.m.·Ireland

Read Full Article

Benzinga

Novo Nordisk Withdraws Wegovy FDA Heart Failure Submission, Terminates Development Of Two Early Stage Assets - Novo Nordisk (NYSE:NVO)

Earlier on Wednesday, Denmark’s most valuable company, Novo Nordisk A/S (NYSE:NVO), reported second-quarter earnings that missed the analyst consensus. In its quarterly earnings presentation, Novo Nordisk said that in January 2024, it submitted the results from Wegovy STEP HFpEF trials for regulatory review in the US and EU. Based on interactions with the FDA, the company has decided to withdraw the file. It expects to resubmit the file at the b…

08/07/2024 5:55:16 p.m.·New York, United States

Read Full Article

Bloomberg

Novo Cuts Annual Profit Forecast as Wegovy Sales Fall Short

Novo Nordisk A/S cut its profit forecast for the year as its blockbuster weight-loss drug Wegovy fell short of analysts’ expectations for quarterly sales.

08/07/2024 5:43:17 a.m.·United States

Read Full Article